The Latest Study to Assess the Efficacy of Nicotinamide Riboside (NR), “Nicotinamide Riboside Supplementation is Well-Tolerated and Effectively Elevates NAD+ in Healthy Middle-Aged and Older Adults,”
– published in Nature Communications suggests it potentially improves blood pressure and cardiovascular health.
The objective of the CU Boulder study? To confirm the increase in NAD due to NR supplementation. Likewise, the study aimed to identify potential end-points for future studies that are targeted at reducing age-related physiological dysfunction, says Christopher Martens, the lead author of the paper.
- NR supplementation increased NAD levels by 60% on average, compared with a placebo.
- Consuming NIAGEN daily mimics caloric restriction, kick-starting many of the same key chemical pathways responsible for its health benefits.
- Use of NAD precursors to augment NAD bioavailability has been proposed as a strategy for improving cardiovascular and other physiological functions with aging.
With the release of this study’s exciting results, there’s never been a better time to address your cellular health.
The latest study to assess the efficacy of chronic nicotinamide riboside supplementation in a six-week randomized, double-blind, placebo-controlled, crossover clinical trial. Thirty healthy middle-aged men and women between the ages of 55 and 79 consumed 500mg of NIAGEN® nicotinamide riboside (NR) twice daily. The authors assessed a broad range of physiological factors known to decline with advancing age. This is the first study to show increased NAD levels do more than simply increase NAD.
Increased Levels of NAD
The CU Boulder study shows that NR supplementation effectively increased NAD levels 60% in average, compared with a placebo. In people with low baseline blood cellular NAD levels, the study suggests an even greater response. Even just a single dose of NIAGEN® is proven to significantly increase NAD, but we now know that continued use maintains the elevated NAD levels.
“The decreased availability of cellular energy in the central nervous system is now thought to be a contributing factor in cognitive decline, notes Dr. Rudolph Tanzi, the Vice-Chair of Neurology and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital, the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School, and a member of the ChromaDex Scientific Advisory Board. “This study took the science a step further by noting that NR trended towards increasing ATP, which is needed for the cellular energy the body and brain need.”
The Potential for Cardiovascular Health
In this study, 13 of the participants with elevated blood pressure or stage 1 hypertension (120–139/80–89 mmHg), systolic blood pressure was about 10 points lower after supplementation, on average. Based on these findings, the authors concluded that future clinical trials with NIAGEN should assess its role in supporting cardiovascular health.
Consuming NIAGEN daily mimics caloric restriction, which kick-starts many of the same key chemical pathways responsible for its health benefits. Alongside the dietary changes and exercise currently recommended by the American Heart Association, such CR-mimicking compounds could provide an additional support for people looking to proactively manage their heart health.
The Research Team
Lead Author: Christopher Martens, PhD
Previously Postdoctoral Fellow, Department of Integrative Physiology, University of Colorado, Boulder. Currently Assistant Professor, Department of Kinesiology & Applied Physiology, University of Delaware.
Senior Author: Douglas Seals, PhD
Professor of Distinction, Department of Integrative Physiology
University of Colorado Boulder.
Blair A. Denman, Melissa R. Mazzo, Michael L. Armstrong, Nichole Reisdorph, Matthew B. McQueen, Michel Chonchol
1. The American Heart Association’s Diet and Lifestyle Recommendations. 2015 [cited 2018 March 26]; Available from: http://www.heart.org/HEARTORG/HealthyLiving/HealthyEating/Nutrition/The-American-Heart-Associations-Diet-and-Lifestyle-Recommendations_UCM_305855_Article.jsp#.WrmGDC7waCh.
The University of Colorado research is particularly compelling because this placebo controlled study corroborated not only the safety profile of NIAGEN, but also uncovered initial potential that systolic BP was reduced in subjects with pre-hypertension.
Roger Kornberg, ChromaDex Scientific Advisory Board member, Nobel Laureate, and Professor at Stanford Medical School